- Conditions
- Atopic Dermatitis, Eczema, Atopic
- Interventions
- ALX-101 Gel 1.5% and ALX-101 Gel Vehicle, ALX-101 Gel 5% and ALX-101 Gel Vehicle
- Drug
- Lead sponsor
- Ralexar Therapeutics, Inc.
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 209 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 35
- States / cities
- Anniston, Alabama • Birmingham, Alabama • Laguna Hills, California + 28 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Retinitis Pigmentosa
- Interventions
- N-acetylcysteine, Placebo
- Drug
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 485 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2030
- U.S. locations
- 24
- States / cities
- Davis, California • Los Angeles, California • San Francisco, California + 21 more
- Conditions
- Type 2 Diabetes, Cardiovascular Disease
- Interventions
- TAK-875, TAK-875 Placebo
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 3,207 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 218
- States / cities
- Birmingham, Alabama • Dothan, Alabama • Mobile, Alabama + 215 more
- Conditions
- Metastatic Pancreatic Cancer
- Interventions
- Olaratumab, Nab-paclitaxel, Gemcitabine, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 184 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 32
- States / cities
- Scottsdale, Arizona • Tucson, Arizona • Fayetteville, Arkansas + 26 more
- Conditions
- Advanced Solid Tumors, Ovarian Cancer, Endometrial Cancer, Cholangiocarcinoma, CNS Tumor
- Interventions
- PHST001, Chemotherapy per Standard of Care
- Biological · Drug
- Lead sponsor
- Pheast Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 272 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2031
- U.S. locations
- 20
- States / cities
- Beverly Hills, California • Los Angeles, California • Palo Alto, California + 15 more
- Conditions
- Esophageal Neoplasms, Adenocarcinoma of the Gastroesophageal Junction, Gastroesophageal Cancer, Squamous Cell Carcinoma, Gastric Adenocarcinoma
- Interventions
- DKN-01 150 mg, Paclitaxel, Pembrolizumab, DKN-01 300 mg
- Drug
- Lead sponsor
- Leap Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 151 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2021
- U.S. locations
- 10
- States / cities
- Los Angeles, California • New Haven, Connecticut • Chicago, Illinois + 5 more
- Conditions
- Renal Cell Carcinoma
- Interventions
- HC-7366, Belzutifan
- Drug
- Lead sponsor
- HiberCell, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 20
- States / cities
- Tucson, Arizona • La Jolla, California • Los Angeles, California + 14 more
- Conditions
- Hearing Loss, Sensorineural, Presbycusis
- Interventions
- Audiologist-based fitting, Over-the-counter fitting
- Device
- Lead sponsor
- Yu-Hsiang Wu
- Other
- Eligibility
- 18 Years to 89 Years
- Enrollment
- 360 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 2
- States / cities
- Iowa City, Iowa • Nashville, Tennessee
- Conditions
- AML/MDS
- Interventions
- Mana 312
- Biological
- Lead sponsor
- Mana Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 8
- States / cities
- Denver, Colorado • Atlanta, Georgia • Kansas City, Kansas + 4 more
- Conditions
- Advanced Solid Tumor
- Interventions
- ZL-1211
- Drug
- Lead sponsor
- Zai Biopharmaceutical (Suzhou) Co., Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 10
- States / cities
- Scottsdale, Arizona • Lynwood, California • Indianapolis, Indiana + 7 more
- Conditions
- Breast Cancer
- Interventions
- trastuzumab emtansine
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 4
- States / cities
- Fort Myers, Florida • Detroit, Michigan • Portland, Oregon + 1 more
- Conditions
- Metastatic Prostate Cancer
- Interventions
- High dose testosterone
- Drug
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 51 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 17
- States / cities
- Aurora, Colorado • West Haven, Connecticut • Gainesville, Florida + 14 more
- Conditions
- Upper Extremity Fracture, Upper Extremity Dislocation, Fractures, Comminuted, Elbow Fracture, Elbow Dislocation
- Interventions
- JAS Brace
- Device
- Lead sponsor
- Vanderbilt University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2009
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Dry Eye Disease
- Interventions
- 0.2 % hemigalactarate (0.11% free base) 0.2 % OC-02 Low Dose (1.1 mg/mL), 1.0 % hemigalactarate (0.11% free base) 1.0 % OC-02 Mid Dose (5.5 mg/mL), 2.0 % hemigalactarate (0.11% free base) 2.0 % OC-02 High Dose (11.1 mg/mL), Placebo (vehicle) nasal spray
- Drug
- Lead sponsor
- Oyster Point Pharma, Inc.
- Industry
- Eligibility
- 22 Years and older
- Enrollment
- 165 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018
- U.S. locations
- 3
- States / cities
- Louisville, Kentucky • Andover, Massachusetts • Nashville, Tennessee
- Conditions
- Crohn's Disease
- Interventions
- placebo for risankizumab IV, risankizumab SC, risankizumab IV
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 16 Years to 80 Years
- Enrollment
- 618 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 114
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Tempe, Arizona + 89 more
- Conditions
- Late Life Depression, Cognitive Decline, Depressive Disorder, Treatment-Resistant, Levodopa, Gait Impairment
- Interventions
- L-Dopa, Placebo
- Drug
- Lead sponsor
- Vanderbilt University Medical Center
- Other
- Eligibility
- 60 Years and older
- Enrollment
- 79 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2026
- U.S. locations
- 2
- States / cities
- Pittsburgh, Pennsylvania • Nashville, Tennessee
- Conditions
- Pneumonia, Skin and Soft Tissue (SST) Infection, Urinary Tract Infections (UTIs)
- Interventions
- Study Drug Placebo
- Drug
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 60 Days to 17 Years
- Enrollment
- 1,200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 10
- States / cities
- Birmingham, Alabama • Aurora, Colorado • Washington D.C., District of Columbia + 6 more
- Conditions
- Ventricular Tachycardia
- Interventions
- FlexAbility SE Ablation Catheter
- Device
- Lead sponsor
- Abbott Medical Devices
- Industry
- Eligibility
- 7 Years and older
- Enrollment
- 62 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 11
- States / cities
- Naples, Florida • Indianapolis, Indiana • Overland Park, Kansas + 8 more
- Conditions
- Breast Cancer
- Interventions
- ARV-471 in combination with Everolimus
- Drug
- Lead sponsor
- Arvinas Estrogen Receptor, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 6
- States / cities
- San Diego, California • Santa Monica, California • Washington D.C., District of Columbia + 3 more
- Conditions
- Locally Advanced Solid Tumors, Recurrent Solid Tumors, Metastatic Solid Tumors
- Interventions
- RO7566802, Atezolizumab
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 250 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 6
- States / cities
- Birmingham, Alabama • New Haven, Connecticut • New York, New York + 3 more
- Conditions
- Acute Graft Versus Host Disease, Hematopoietic and Lymphatic System Neoplasm, Leukemia, Lymphoma
- Interventions
- Allogeneic Hematopoietic Stem Cell Transplantation, Lactobacillus plantarum strain 299, Lactobacillus plantarum strain 299v, Placebo Administration
- Procedure · Biological · Other
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- 2 Years to 25 Years
- Enrollment
- 173 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2026
- U.S. locations
- 40
- States / cities
- Birmingham, Alabama • Duarte, California • Los Angeles, California + 35 more
- Conditions
- Chronic Kidney Disease (CKD)
- Interventions
- Epoetin Hospira Arm, Standard of Care Arm, IV Iron
- Biological · Other · Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 432 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 42
- States / cities
- Chula Vista, California • Poway, California • Rancho Bernardo, California + 24 more
- Conditions
- Brain and Central Nervous System Tumors
- Interventions
- tamoxifen citrate, radiation therapy
- Drug · Radiation
- Lead sponsor
- Radiation Therapy Oncology Group
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 77 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2000
- U.S. locations
- 237
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 184 more
- Conditions
- HIV Infections, Hepatitis C, Liver Disease
- Interventions
- Peginterferon alfa-2a, Ribavirin
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 333 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2009
- U.S. locations
- 36
- States / cities
- Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 23 more